Vancomycin Calculator Dosing, AUC/MIC & Drug Level Monitoring
Vancomycin Calculator
Estimate adult vancomycin loading dose, maintenance dose, dosing interval and predicted steady-state levels using Cockcroft-Gault creatinine clearance and population pharmacokinetics (AUC-guided).
This calculator provides population-based estimates for adults (18+) with stable renal function and is for informational and educational use only. It does not replace clinical judgment. Not for dialysis, unstable renal function, pregnancy, burns or other special populations without clinical review. Confirm all doses with a qualified clinician or pharmacist and individualize using measured vancomycin levels.
This vancomycin calculator uses population pharmacokinetic estimates, Bayesian modeling, and the Sawchuk-Zaske method to determine an appropriate vancomycin dosing regimen for adult patients. It can calculate an initial regimen empirically, without previous doses, or adjust dosing based on one or two measured vancomycin levels.
The calculator estimates pharmacokinetic parameters and determines vancomycin dosing strategies through the following steps:
1. Estimate CLvanco and Vd
Empiric dosing (without drug levels): CLvanco and Vd are estimated using population-based pharmacokinetic models. The selected clearance method determines CLvanco (see Methods for Determining Vancomycin Clearance), while Vd is calculated using the chosen volume of distribution method (see Methods for Determining Vancomycin Volume of Distribution).
One drug level available (trough): Vd is estimated using either a population-based value or a user-defined value. Clearance is then calculated through the following steps:
- Use a population-based clearance estimate to extrapolate the true trough concentration if the sample was collected earlier or later than scheduled.
- Use a population-based Vd estimate to extrapolate the peak concentration.
- Calculate Kel and CLvanco using the extrapolated peak and trough concentrations.
Two drug levels available (peak and trough): This approach provides the most accurate patient-specific estimates of CLvanco and Vd, but requires two measured drug concentrations. These pharmacokinetic parameters are calculated using the Sawchuk-Zaske method.
2. Optimize CLvanco and Vd using Bayesian modeling (if selected)
When only one drug level is available, Bayesian modeling can refine the population-based estimates of CLvanco and Vd to better reflect the individual patient’s pharmacokinetics. This feature can be turned off by selecting “Population Estimates” under the “Preferred modeling method” setting.
Bayesian modeling starts with population estimates of CLvanco and Vd, known as a Bayesian prior, and adjusts them using the patient’s measured drug level. For example, the model may refine a population-based Vd estimate of 0.98 L/kg to an optimized value of 1.11 L/kg based on the patient’s drug concentration. For further details, see Vancomycin Bayesian Modeling.
Bayesian modeling is not performed when no drug levels are available, because the model requires at least one measured concentration. It is also not used when two drug levels are available, as the Sawchuk-Zaske method provides more reliable patient-specific pharmacokinetic estimates in that situation.
3. Use one-compartment PK equations to estimate peak, trough, and AUC/MIC
Once CLvanco, Vd, and Kel have been established, one-compartment pharmacokinetic equations are used to predict peak and trough concentrations and calculate the AUC/MIC ratio for a specific dosing regimen.
Predicted Peak and Trough
\[ C_{\text{peak}}= \frac{Dose(1-e^{-Kel \cdot T_{\text{inf}}})} {T_{\text{inf}}\cdot Vd\cdot Kel(1-e^{-Kel\cdot Tau})} \]
\[ C_{\text{trough}}=C_{\text{peak}}\cdot e^{-Kel(Tau-T_{\text{inf}})} \]
AUC Method #1
First, calculate the linear and logarithmic trapezoidal areas:
\[ L_{\text{trap}}=\frac{C_{\text{trough}}+C_{\text{peak}}}{2}\cdot T_{\text{inf}} \]
\[ Log_{\text{trap}}= \frac{(C_{\text{peak}}-C_{\text{trough}})(Tau-T_{\text{inf}})} {\ln(C_{\text{peak}}/C_{\text{trough}})} \]
Then, calculate the AUC over the dosing interval and convert it to a 24-hour value:
\[ AUC_{0-\text{Tau}}=L_{\text{trap}}+Log_{\text{trap}} \]
\[ AUC_{0-24}=AUC_{0-\text{Tau}}\cdot\frac{24}{Tau} \]
The resulting AUC is expressed in mcg·h/mL.
AUC Method #2
Calculate vancomycin clearance using:
\[ CL_{\text{vanco}}=Kel\cdot Vd \]
Then determine the 24-hour AUC:
\[ AUC_{0-24}= \frac{\text{Total daily vancomycin dose}}{CL_{\text{vanco}}} \]
Convert AUC to the AUC:MIC ratio over 24 hours
Finally, divide the 24-hour AUC by the minimum inhibitory concentration (MIC):
\[ AUC_{0-24}:MIC=\frac{AUC_{0-24}}{MIC} \]
Vancomycin Pharmacokinetic Models and Population Estimates
When CLvanco or Vd values are not known, population-based estimates derived from published research can be used. Many pharmacokinetic textbooks recommend a fixed Vd, such as 0.7 L/kg, or estimate CLvanco as 70% of creatinine clearance. However, research shows that these estimates can vary considerably among specific patient groups, including individuals with morbid obesity and critically ill patients. To account for these differences, this calculator uses one of four pharmacokinetic models to estimate a patient’s parameters:
- Buelga et al., 2005: 1 — The default model for general hospitalized adult patients.
- Adane et al., 2015: 2 — Designed for patients with extreme obesity (BMI > 40 kg/m² and body weight ≥ 120 kg).
- Roberts et al., 2011: 3 — Intended for critically ill ICU patients with a BMI < 30 kg/m².
- Masich et al., 2020: 4 — Developed for critically ill patients with obesity (BMI ≥ 30 kg/m² and body weight > 100 kg).
Numerous models are available for pharmacokinetic and Bayesian analyses, as described in references 5 and 6. These four models were chosen because they are generalizable, use a one-compartment approach, and have demonstrated reasonable predictive performance in validation studies.
The models can produce substantially different estimates because they were developed using different patient populations. This highlights the importance of selecting the model that best represents the individual patient. For example, consider a patient weighing 100 kg with a creatinine clearance of 80 mL/min and a body surface area (BSA) of 2.3 m². The initial pharmacokinetic estimates from each model would be as follows:
| Model | Intended patient population | CLvanco (L/hr) | Vd (L/kg) | Half-life (hr) |
|---|---|---|---|---|
| Buelga 2005 1 | General hospitalized patients | 5.18 | 0.98 | 13.1 |
| Adane 2015 2 | Extreme obesity | 4.19 | 0.51 | 8.4 |
| Roberts 2011 3 | Critically ill patients | 4.65 | 1.53 | 22.8 |
| Masich 2020 4 | Critically ill patients with obesity | 5.21 | 0.78 | 10.4 |
Methods for Determining Vancomycin Clearance
The following methods can be used to estimate vancomycin clearance.
Bayesian Modeling Population Estimates [Preferred Method]
CLvanco is estimated using the most appropriate published pharmacokinetic model for the individual patient. The following models and their corresponding clearance equations are used:
| Model | Intended patient population | CLvanco Equation |
|---|---|---|
| Buelga 2005 | General hospitalized patients | |
| Adane 2015 | Extreme obesity | |
| Roberts 2011 | Critically ill patients | |
| Masich 2020 | Critically ill patients with obesity |
Bauer Method [7]
CLvanco is estimated using a linear relationship with creatinine clearance, adjusted for total body weight.
Matzke Method [8]
CLvanco is estimated using a linear relationship with creatinine clearance.
Note that this method comes from the same publication that introduced the linear relationship between Kel and CrCl, expressed as Kel = 0.00083 × CrCl + 0.0044. This relationship is sometimes referred to as the Creighton equation.
Methods for Determining Vancomycin Volume of Distribution
Several methods are available to estimate the vancomycin volume of distribution (Vd).
Bayesian Modeling Population Estimates [Preferred Method]
Vd is estimated using the most suitable published pharmacokinetic model for the patient. The following models provide the corresponding Vd values:
| Model | Intended patient population | Vd (L/kg TotalBW) |
|---|---|---|
| Buelga 2005 | General hospitalized patients | 0.98 |
| Adane 2015 | Extreme obesity | 0.51 |
| Roberts 2011 | Critically ill patients | 1.53 |
| Masich 2020 | Critically ill patients with obesity | 0.78 |
Bauer Method [7]
This method uses a fixed Vd estimate of 0.7 L/kg, a value commonly cited in pharmacokinetic textbooks.
Matzke Method [8]
This method estimates Vd according to the patient’s creatinine clearance (CrCl):
| CrCl (mL/min) | Vd (L/kg) |
|---|---|
| > 60 | 0.72 |
| ≤ 60 | 0.89 |
Rushing-Ambrose Method [9]
This method calculates Vd using an equation that incorporates the patient’s age (in years) and total body weight (in kg).
Morbid Obesity [2], [10]
In non-critically ill patients with morbid obesity, defined as a BMI > 40 kg/m² and body weight ≥ 120 kg, Vd per kilogram of total body weight tends to be lower. Although individual values can vary considerably, a Vd estimate of 0.52 L/kg is a reasonable population-based value supported by published literature.
User-Specified Vd
Users who prefer to apply a specific volume of distribution value in L/kg can select this option and enter their desired Vd estimate.
Vancomycin Bayesian Modeling for CLvanco and Vd
Bayesian modeling estimates a patient’s vancomycin clearance (CLvanco) and volume of distribution (Vd) using a single vancomycin concentration measurement. This measurement can be collected at steady state or after just one dose. The process involves several mathematically complex steps:
1. Select an appropriate pharmacokinetic model: Identify a published study reporting the mean and variance of vancomycin clearance and volume of distribution. The study population should have characteristics similar to those of the patient receiving vancomycin.
2. Measure vancomycin concentration: Obtain one or more vancomycin blood concentration measurements from the patient.
3. Optimize CLvanco and Vd: A Bayesian algorithm uses probability to identify the clearance and distribution volume values most likely to explain the measured serum drug concentrations. These estimates are refined using the mean values and variances reported in the selected study.
4. Calculate the elimination constant (Kel): Once CLvanco and Vd are estimated, the elimination rate constant can be calculated from these pharmacokinetic parameters.
5. Determine the dosing regimen: With the estimated Kel and Vd, one-compartment pharmacokinetic equations are used to determine an appropriate dose and predict the associated peak concentration, trough concentration, and AUC/MIC ratio.
Sawchuk-Zaske Method for Kel and Vd
When multiple vancomycin concentrations are available, traditional pharmacokinetic equations can be used to determine patient-specific pharmacokinetic parameters. This approach is known as the Sawchuk-Zaske method [11]. Unlike Bayesian analysis, it does not rely on population-based kinetic estimates and may provide more reliable results, particularly for patients with substantially altered pharmacokinetics.
The Sawchuk-Zaske method uses two post-dose drug concentrations, whether or not the patient has reached steady state. The process involves the following steps [11]:
1. Determine Kel
Cp0 represents the first (higher) concentration, Cp is the second (lower) concentration, t is the time elapsed between the two measurements, and k is the elimination constant (Kel).
2. Extrapolate to Cmax (peak) and Cmin (trough)
Using the first-order elimination equation, the actual peak concentration (Cmax) can be estimated from the time between the end of the vancomycin infusion and the first measured concentration (Cp0). Similarly, the actual trough concentration (Cmin) can be calculated using the time between the second measurement (Cp) and the scheduled start of the next infusion.
3. Calculate volume of distribution (Vd)
A patient-specific Vd can be calculated using the Cmax and Cmin values obtained in the previous step. If the patient has received only one dose and has not reached steady state, Cmin is assumed to be zero.
Vd represents the volume of distribution in liters; dose is the vancomycin dose in milligrams; Tinf is the infusion duration in hours; k is the elimination constant (Kel, in hr⁻¹); Cmax is the actual peak concentration; and Cmin is the actual trough concentration at steady state or zero if the patient has not reached steady state.
4. Use patient-specific Kel and Vd for additional calculations
After determining the patient’s Kel and Vd, traditional one-compartment pharmacokinetic equations can be applied to calculate an appropriate dosing regimen and predict the associated peak concentration, trough concentration, and AUC/MIC ratio.
Vancomycin Drug Level Monitoring
The preferred approach for monitoring vancomycin therapy is to measure two drug concentrations, such as peak and trough levels, within the same dosing interval. These samples can be collected after the first dose, before steady state is reached, or after steady state has been achieved, typically following the third dose. Measuring two concentrations allows patient-specific pharmacokinetic parameters to be estimated using the Sawchuk-Zaske method.
Two drug levels collected after a single dose (non-steady state)
Two drug levels collected at steady state (after at least three doses)
Because trough-only monitoring has long been used in vancomycin therapy, some healthcare institutions may prefer measuring a single concentration, usually a trough level. This sample can be collected after the first dose or once steady state has been reached, typically after the third dose. Although measuring one concentration is more convenient and less expensive, estimating pharmacokinetic parameters requires Bayesian modeling. This approach may be less accurate than the two-level method, particularly in patients with significantly altered pharmacokinetics, such as those with extreme obesity, critical illness, pregnancy, or severe burns.
One drug level collected after a single dose (non-steady state)
One drug level collected at steady state (after at least three doses)
Vancomycin Loading Dose
For selected patients, a loading dose of 25–30 mg/kg based on total body weight, up to a maximum of 3,000 mg, may be considered to achieve therapeutic serum concentrations more rapidly. Patients who may benefit include those who are critically ill, receiving renal replacement therapy, or undergoing continuous vancomycin infusion. This recommendation is based on expert opinion rather than clinical trial evidence.
Inappropriate Populations for This Calculator
This calculator is not intended for the following patient groups, or its results may require additional clinical judgment:
- Patients receiving renal replacement therapy (RRT)
- Patients with unstable renal function
- Patients with a vancomycin MIC ≥ 2 mcg/mL
- Pediatric patients younger than 18 years
- Patients with cystic fibrosis
- Patients with severe burn injuries
Dosing Recommendations for Renal Replacement Therapy (RRT)
Vancomycin dosing in patients receiving renal replacement therapy is complex and generally requires specialist guidance alongside an assessment of individual patient factors. Several variables can influence dosing requirements, including blood flow rate, filter type, hemodialysis frequency and downtime, effluent rate, and residual renal function. The following recommendations provide general guidance for this patient population.
Intermittent Hemodialysis [12]
An initial loading dose of 25 mg/kg is recommended, followed by 7.5–10 mg/kg after each hemodialysis session. Blood samples can be collected before dialysis or 1–2 hours after its completion. These concentrations should guide maintenance dose adjustments toward a target AUC/MIC of 400–600 mg·h/L.
Sustained Low-Efficiency Dialysis (SLED) [12], [13]
A loading dose of 20–25 mg/kg is recommended, followed by 15 mg/kg after each hybrid hemodialysis session. Blood samples may be collected before dialysis or 1–2 hours after the session ends. Results should guide maintenance dosing toward a target AUC/MIC of 400–600 mg·h/L.
Continuous Renal Replacement Therapy (CRRT) [14]
A loading dose of 15–25 mg/kg is recommended, followed by maintenance dosing tailored to the CRRT modality. Blood concentrations should be monitored to adjust maintenance therapy toward a target AUC/MIC of 400–600 mg·h/L.
- CVVH: 10–15 mg/kg every 24–48 hours
- CVVHD: 10–15 mg/kg every 24 hours or 7.5 mg/kg every 12 hours
- CVVHDF: 7.5–10 mg/kg every 12 hours
FAQs
Conclusion
The vancomycin calculator combines population pharmacokinetic models, Bayesian modeling, and the Sawchuk-Zaske method to estimate patient-specific dosing, predict drug concentrations, and calculate AUC/MIC. By considering factors such as body weight, renal function, critical illness, and measured vancomycin levels, it helps clinicians better understand dosing options and individual pharmacokinetic differences. However, its results must be interpreted carefully, particularly in complex patients and populations for whom the calculator is not intended, with clinical judgment and appropriate drug-level monitoring remaining essential.
Read More:
